One Pot Stock Could Skyrocket With Looming Interstate Sales
A new bill in Congress would decriminalize marijuana nationally by removing cannabis from the federal government’s list of controlled substances. The law would also allow one established Seattle cannabis company to market across state lines for the first time – potentially setting off a bidding war that could blast this stock into the stratosphere!
Find Out Why This Could Be the #1 Pot Stock
Douglas S. Ingram, insider at Sarepta Therapeutics
Douglas S. Ingram Insider Alerts

Get notified the next time Douglas S. Ingram buys or sells Sarepta Therapeutics stock. Enter your email address below to get our daily insider buying and selling report.

Douglas S. Ingram Insider Information

Doug Ingram has served as President, CEO, and board member since 2017. He has no ambiguity about Sarepta’s mission:

“We know why we get up every day and work as hard as we do. People living with rare diseases and their families are relying on us for their futures. We’re in a position to extend and change the lives of so many people. The opportunity to do good is just breathtaking.”

Doug has a single-minded focus to make Sarepta the leader in precision genetic medicine and rescue lives devastated by rare genetic disease. “I saw something in Sarepta that was special. An opportunity to be part of something important. Much of what we’re doing has never been done before. It has the potential to upend the entire medical system.”

Doug likes to make clear that Sarepta is different from most biotechs clustered around Kendall Square in Cambridge. “We’re a commercial-stage organization with the resources to bring precision genetic medicine from discovery all the way to the patient.”

Doug’s two decades in the pharma-biotech world began at Allergan, which he joined as General Counsel in 2001, holding positions of increasing responsibility until being named President in 2013. When Allergan was acquired by Actavis in 2016, he moved on to Chase Pharmaceuticals, serving as President and CEO before coming to Sarepta.

Doug received his JD from the University of Arizona and his BS from Arizona State University. He sits on Relay Therapeutics’ Board of Directors.

What is Douglas S. Ingram's net worth?

The estimated net worth of Douglas S. Ingram is at least $33.89 million as of August 12th, 2019. Mr. Ingram owns 424,405 shares of Sarepta Therapeutics stock worth more than $33,892,983 as of November 30th. This net worth estimate does not reflect any other assets that Mr. Ingram may own. Learn More.

What is Douglas S. Ingram's salary?

As the CEO of Sarepta Therapeutics, Inc., Mr. Ingram earned a total compensation package of $1,291,947.00 in 2020. Mr. Ingram earned a salary of $669,250.00, non-equity compensation of $605,475.00, and other compensation of $17,222.00.

How do I contact Douglas S. Ingram?

The corporate mailing address for Mr. Ingram and other Sarepta Therapeutics executives is 215 FIRST STREET SUITE 415, CAMBRIDGE MA, 02142. Sarepta Therapeutics can also be reached via phone at (857) 242-4000 and via email at [email protected]

Has Douglas S. Ingram been buying or selling shares of Sarepta Therapeutics?

During the past quarter, Douglas S. Ingram has bought $2,000,578.00 of Sarepta Therapeutics stock. Most recently, on Wednesday, November 17th, Douglas S. Ingram bought 25,026 shares of Sarepta Therapeutics stock. The stock was acquired at an average cost of $79.94 per share, with a total value of $2,000,578.44.

Are insiders buying or selling shares of Sarepta Therapeutics?

In the last twelve months, Sarepta Therapeutics insiders bought shares 2 times. They purchased a total of 28,806 shares worth more than $2,300,445.84. In the last twelve months, insiders at the biotechnology company sold shares 4 times. They sold a total of 17,240 shares worth more than $1,627,875.00. The most recent insider tranaction occured on November, 24th when insider Louise Rodino-Klapac bought 3,780 shares worth more than $299,867.40. Insiders at Sarepta Therapeutics own 5.9 % of the company.

Information on this page was last updated on 11/24/2021.

Douglas S. Ingram Insider Trading History at Sarepta Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/17/2021Buy25,026$79.94$2,000,578.44View SEC Filing Icon  
8/12/2019Buy16,252$123.07$2,000,133.64424,405View SEC Filing Icon  
10/30/2018Buy16,695$120.39$2,009,911.05412,811View SEC Filing Icon  
8/15/2018Buy16,000$125.26$2,004,160.00399,250View SEC Filing Icon  
11/8/2017Buy38,138$52.44$1,999,956.72420,196View SEC Filing Icon  
7/27/2017Buy47,058$42.50$1,999,965.00382,058View SEC Filing Icon  
See Full Table

Douglas S. Ingram Buying and Selling Activity at Sarepta Therapeutics

This chart shows Douglas S Ingram's buying and selling at Sarepta Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Sarepta Therapeutics Company Overview

Sarepta Therapeutics logo
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.
Read More

Today's Range

Now: $79.86
Low: $79.76
High: $81.83

50 Day Range

MA: $85.63
Low: $77.28
High: $99.42

2 Week Range

Now: $79.86
Low: $65.30
High: $181.83

Volume

596,871 shs

Average Volume

1,308,826 shs

Market Capitalization

$6.95 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.21
Biden Warns: China Could "Eat Our Lunch" When it Comes to Lithium
Pres. Biden recently warned about China's dominance when it comes to lithium demand, stating, "if we don't get moving, they're going to eat our lunch." One junior mining company in South America is looking to become a strong link in the lithium supply chain due to a monster acquisition.
Get the full scoop on this investment opportunity